The offering closes July 31, 2026, creating near-term overhang from the discounted placement and warrant overhang. The key catalyst is the October 30 PDUFA for INO-3107; failure to secure accelerated approval would likely force further dilutive financing or a strategic alternative. Monitor for FDA feedback on accelerated approval eligibility and any updates on the shareholder litigation.
Price Chart
Executive Summary
Inovio Pharmaceuticals (INO) is raising ~$18.3M net via a 424B5 takedown from its $300M shelf, selling 21.1M shares and warrants for 42.1M shares at $0.95/unit (a ~8% discount to the $1.03 close). The company also disclosed a going-concern risk, preliminary cash of $36.7M as of June 30, 2026, and that the FDA has not yet ruled on INO-3107's accelerated approval eligibility ahead of the October 30 PDUFA date. This offering adds ~30% immediate dilution from shares alone, with potential for further dilution from the 2:1 warrant coverage.
Key Facts
- Offering of 21,052,632 shares and warrants for 42,105,264 shares at $0.95/unit, raising ~$18.3M net ($20M gross)
- Warrants exercisable at $1.10/share for 5 years; no public market expected for warrants
- Pro forma as-adjusted net tangible book value per share of $0.58 vs. offering price of $0.95 = $0.37 immediate dilution per share
- Company discloses 'substantial doubt exists as to our ability to continue as a going concern'
- Preliminary cash and cash equivalents of ~$36.7M as of June 30, 2026
- PDUFA target date for INO-3107 BLA is October 30, 2026; FDA has not provided feedback on accelerated approval eligibility
- Shareholder class action (Feb 2026) and three derivative lawsuits filed against the company and officers
- Proceeds intended for potential commercial launch of INO-3107, confirmatory trial, pipeline development, and general corporate purposes
Financial Impact
Immediate dilution of ~30% from shares (21.1M new shares on ~69.8M pre-offering outstanding), plus potential additional dilution from 42.1M warrants (2:1 ratio) at $1.10 exercise price. Net proceeds of ~$18.3M extend runway into late Q1 2027 per management.
Risk Factors
- FDA may deny accelerated approval for INO-3107, requiring a costly Phase 3 trial or alternative path
- Warrant exercise at $1.10 (above current $1.03 price) is unlikely near-term, but cashless exercise could still add dilution
- Going-concern risk if capital is insufficient to fund operations through potential launch
- Shareholder class action and derivative lawsuits could result in material damages or management distraction
- Frequent capital raises (12 filings in 24 months) signal ongoing cash burn and potential for further dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-326370 |
| Document: 0001193125-26-326370-index-headers.html | 0001193125-26-326370 |
| Document: 0001193125-26-326370-index.html | 0001193125-26-326370 |
| Document: 0001193125-26-326370.txt | 0001193125-26-326370 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 31, 2026 9w ago | 8-K | $0.6770 $1.29 | ▼ −90.55% | ▼ −87.56% | $1.20 (−76.51%) |
Jul 30, 2026 9w ago | 424B5 | $0.6770 $1.29 | ▼ −90.55% | ▼ −87.56% | $1.20 (−76.51%) |
Jul 30, 2026 9w ago | Press Release | $0.6560 $1.26 | ▼ −92.07% | ▼ −88.11% | $1.20 (−82.16%) |
Jul 13, 2026 11w ago | EFFECT | $1.16 $0.7364 | ▲ +36.52% | ▲ +39.70% | $1.20 (−3.02%) |
Jul 2, 2026 13w ago | S-3 | $1.22 $0.6560 | ▲ +46.23% | ▲ +45.81% | $1.20 (+2.05%) |
Jun 11, 2026 16w ago | Institutional Cluster | $1.10 $1.19 | ▲ +8.18% | ▲ +6.29% | $1.20 (+8.64%) |
Apr 6, 2026 25w ago | 8-K | $1.13 $1.14 | ▼ −0.89% | ▲ +8.10% | $1.20 (−5.75%) |
Apr 2, 2026 26w ago | 424B5 | $1.13 $1.12 | ▲ +0.89% | ▲ +10.76% | $1.20 (−5.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access